Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21110936 | 0.98 | KCNH2 (0.32) | KCNH2KMT2ATNKS | |
| SCHEMBL18235318 | 0.82 | KMT2A (0.31) | KMT2A | |
| SCHEMBL18235319 | 0.82 | KCNH2 (0.31) | KCNH2KMT2A | |
| SCHEMBL17946249 | 0.82 | KMT2A (0.31) | KMT2ATDP1 | |
| SCHEMBL18472183 | 0.76 | KCNH2 (0.33) | KCNH2KMT2ALPO | |
| SCHEMBL18573047 | 0.76 | ALDH1A1 (0.31) | KMT2A | |
| SCHEMBL2930973 | 0.73 | ALDH1A1 (0.38) | KMT2ATDP1LPO | |
| SCHEMBL419709 | 0.73 | KMT2A (0.50) | KCNH2KMT2ALPO | |
| SCHEMBL21341550 | 0.71 | TDP1 (0.30) | TDP1LPO | |
| SCHEMBL6354069 | 0.71 | TDP1 (0.30) | TDP1LPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896607-B | Olefin oligomerization process using a catalyst comprising a chromium complex having a phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-4582844-A | Antithrombotic 4,5 di-t-butyl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1986-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | C9, CFB, C5 | KCNH2 3735/4885KMT2A 4463/4885TNKS 3216/4885 |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | KCNH2 788/4885KMT2A 48/4885TNKS 1224/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | KCNH2 244/4885KMT2A 2249/4885TNKS 2350/4885 |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | KCNH2 4741/4885KMT2A 2866/4885TNKS 57/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | KCNH2 1704/4885KMT2A 3835/4885TNKS 3884/4885 |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | KCNH2 1224/4885KMT2A 4052/4885TNKS 4369/4885 |
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | KCNH2 2275/4885KMT2A 2499/4885TNKS 2151/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | KCNH2 4877/4885KMT2A 1342/4885TNKS 682/4885 |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN4 | KCNH2 2990/4885KMT2A 1685/4885TNKS 2055/4885 |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | EPOR, TTPA, PDS5A | KCNH2 4805/4885KMT2A 2782/4885TNKS 721/4885 |
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | KCNH2 2186/4885KMT2A 4169/4885TNKS 3588/4885 |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | KCNH2 1224/4885KMT2A 4052/4885TNKS 4369/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | KCNH2 3909/4885KMT2A 1210/4885TNKS 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.